UroGen Pharma is trading at $34.41, up 5.17%, amid a positive market backdrop and its Phase 1 dosing update; no source explicitly links either to the move.
- On November 2, UroGen announced the first patient was dosed in its Phase 1 trial of UGN-501, an investigational oncolytic virus for bladder cancer; the study will assess safety, tolerability, and feasibility.
- The Dow was up 0.93%; third-quarter results are scheduled for November 4.